On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional ...

As one of the first worldwide suppliers of the influenza vaccines, and now, with over 70 years of innovation in influenza ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

FSHD, or facioscapulohumeral muscular dystrophy, is a neuromuscular disorder characterized by muscle weakness in the face, shoulders and arms. It’s primarily caused ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

The trial investigated the efficacy and safety of a once-daily 10-mg, 20-mg, and 50-mg dose of monlunabant vs. placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...

NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent, costly ...

Sanofi's new medicine, intending to benefit patients with certain forms of multiple sclerosis. Tolebrutinib recently had three Phase 3 readouts and we are pleased already being able to present ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31 per cent, as the French drug maker eyes a request for ...

Sanofi is investing 350 million euros in a new vaccine manufacturing facility at its Canadian headquarters in Toronto. The investment will boost the company's Canadian operations and will be ...